Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer patients.
Sánchez-Muñoz A, Dueñas-García R, Jaén-Morago A, Carrasco E, Chacón I, García-Tapiador AM, Ortega-Granados AL, Martínez-Ortega E, Ribelles N, Fernández-Navarro M, de la Torre-Cabrera C, Dueñas B, Rueda AI, Martínez J, Tortosa CR, Martín-Salvago MD, Sánchez-Rovira P. Sánchez-Muñoz A, et al. Among authors: garcia tapiador am. Am J Clin Oncol. 2010 Oct;33(5):432-7. doi: 10.1097/COC.0b013e3181b4eff9. Am J Clin Oncol. 2010. PMID: 19952716 Clinical Trial.
Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Sánchez-Muñoz A, García-Tapiador AM, Martínez-Ortega E, Dueñas-García R, Jaén-Morago A, Ortega-Granados AL, Fernández-Navarro M, de la Torre-Cabrera C, Dueñas B, Rueda AI, Morales F, Ramírez-Torosa C, Martín-Salvago MD, Sánchez-Rovira P. Sánchez-Muñoz A, et al. Among authors: garcia tapiador am. Clin Transl Oncol. 2008 Oct;10(10):646-53. doi: 10.1007/s12094-008-0265-y. Clin Transl Oncol. 2008. PMID: 18940745 Clinical Trial.
Safety and efficacy of neo-adjuvant sequential dose-dense chemotherapy doublets combined with trastuzumab in patients with HER-2-positive early stage breast cancer.
Sánchez-Muñoz A, García-Tapiador AM, Dueñas-García R, Jaén-Morago A, Ortega-Granados AL, Martínez-Ortega E, Fernández Morales M, Fernández-Navarro M, de la Torre Cabrera C, Dueñas B, Ureña C, Martínez J, Morales F, Ramírez-Tortosa C, Sánchez-Rovira P. Sánchez-Muñoz A, et al. Among authors: garcia tapiador am. Breast J. 2008 Sep-Oct;14(5):506-7. doi: 10.1111/j.1524-4741.2008.00634.x. Epub 2008 Aug 13. Breast J. 2008. PMID: 18705667 No abstract available.
Cross-sensitivity between taxanes in patients with breast cancer.
Sánchez-Muñoz A, Jiménez B, García-Tapiador A, Romero-García G, Medina L, Navarro V, González-Sánchez LA, Alba E. Sánchez-Muñoz A, et al. Clin Transl Oncol. 2011 Dec;13(12):904-6. doi: 10.1007/s12094-011-0753-3. Clin Transl Oncol. 2011. PMID: 22126735
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.
Sastre J, García-Alfonso P, Viéitez JM, Cano MT, Rivera F, Reina-Zoilo JJ, Salud-Salvia A, Quintero G, Robles-Díaz L, Safont MJ, La Casta A, Gil S, Polo E, Asensio-Martínez E, García-Paredes B, López RL, Guillot M, Valladares-Ayerbes M, Aranda E, Díaz-Rubio E; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). Sastre J, et al. ESMO Open. 2021 Apr;6(2):100062. doi: 10.1016/j.esmoop.2021.100062. Epub 2021 Mar 10. ESMO Open. 2021. PMID: 33711671 Free PMC article. Clinical Trial.